MeiraGTx’s Industry-Leading Gene Therapy Manufacturing Facility in Shannon, Ireland Formally Introduced by Head of Irish Government
— Manufacturing facilities built to accelerate development and delivery of advanced medicines to patients using state-of-the-art technology at scale, with quality appropriate for commercialization
Related news for (MGTX)
- 24/7 Market News- MeiraGTx Reports Positive AAV-GAD Study Data
- Graviton Bioscience Announces Strategic Investment from Sanofi to Advance Development of the Next Generation of Selective ROCK2 Inhibitors
- MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million
- MeiraGTx Reports First Quarter 2023 Financial and Operational Results
- MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia